IGC Pharma Expands Ongoing Phase 2 CALMA Clinical Trial Evaluating Investigational Drug Candidate IGC-AD1 For Agitation In Alzheimer's Disease
Benzinga · 10/14 13:02
Share
Listen to the news
IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced the expansion of its ongoing Phase 2 CALMA clinical trial evaluating investigational drug candidate IGC-AD1 for agitation in Alzheimer's disease. The trial has officially opened a new site at the University of South Florida's Department of Psychiatry and Behavioral Neurosciences, under the leadership of Principal Investigator Dr. Ram Bishnoi.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2025 Webull. All Rights Reserved